These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17196075)

  • 61. Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.
    Sethi S; Fogarty C; Hanania NA; Martinez FJ; Rennard S; Fries M; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Dwivedi S; Reisner C
    Chronic Obstr Pulm Dis; 2017 Apr; 4(3):258. PubMed ID: 28853450
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of aerosol formulations of formoterol fumarate and budesonide.
    Nirale NM; Nagarsenker MS; Mendon SB; Chanagare R; Katkurwar A; Lugade V
    Indian J Pharm Sci; 2011 May; 73(3):282-6. PubMed ID: 22457551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England.
    Wilton LV; Shakir SA
    Drug Saf; 2002; 25(3):213-23. PubMed ID: 11945116
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of formoterol in the treatment of stuttering. A pilot study.
    Pesak J; Zapletalova J; Grezl T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Sep; 153(3):199-203. PubMed ID: 19851432
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses.
    Zhang Y; Hubert P; Hubert C
    J Drug Assess; 2022; 11(1):20-25. PubMed ID: 36213210
    [TBL] [Abstract][Full Text] [Related]  

  • 66. (-)-formoterol, a selective beta 2-adrenoreceptor agonist.
    Kurihara H; Fujita S; Mase T
    Acta Crystallogr C; 1997 Dec; 53 ( Pt 12)():1887-9. PubMed ID: 9431660
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.
    Shur J; Lee S; Adams W; Lionberger R; Tibbatts J; Price R
    AAPS J; 2012 Dec; 14(4):667-76. PubMed ID: 22723022
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vitro testing of two formoterol dry powder inhalers at different flow rates.
    Weuthen T; Roeder S; Brand P; Müllinger B; Scheuch G
    J Aerosol Med; 2002; 15(3):297-303. PubMed ID: 12396417
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
    Chew NY; Chan HK
    J Aerosol Med; 2001; 14(4):495-501. PubMed ID: 11791690
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
    Chuchalin AG; Manjra AI; Rozinova NN; Skopková O; Cioppa GD; Till D; Kaiser G; Fashola T; Kottakis J
    J Aerosol Med; 2005; 18(1):63-73. PubMed ID: 15741775
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single-dose capsule inhaler.
    Criée CP; Meyer T; Petro W; Sommerer K; Zeising P
    J Aerosol Med; 2006; 19(4):466-72. PubMed ID: 17196075
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.